Review

phospho cdk2 (Cell Signaling Technology Inc)

Cell Signaling Technology Inc is a verified supplier

Cell Signaling Technology Inc manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Cell Signaling Technology Inc phospho cdk2

A - C EdU flow plots for Karpas-422, RL, and Sc-1 cells after 24-h treatment (Linperlisib 32 μM; Chiglitazar 16 μM). D – F Quantification of EdU-positive cells showing reduced DNA synthesis with the combination ( n = 3). G – L ( G , H ) for Karpas-422; ( I , J ) for RL; ( K , L ) for Sc-1. Cell-cycle distribution by PI staining, demonstrating G0/G1 accumulation with Linperlisib and further enhancement by the combination (Linperlisib 16 μM; Chiglitazar 8 μM; n = 3). M GSEA indicating negative enrichment of the G1/S transition pathway (NES = − 2.85865, p < 0.00001). N – P Western blots of G1/S checkpoint proteins (p27, Cyclin E1, <t>CDK2,</t> p-CDK2); combination treatment increased p27 and decreased Cyclin E1, CDK2, and p-CDK2 (representative of three independent experiments).

Phospho Cdk2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cdk2/pmc13040022-65-65-67
Average 86 stars, based on 1 article reviews

phospho cdk2 - by Bioz Stars, 2026-09

86/100 stars

Images

1) Product Images from "Dual targeting of PI3Kδ and PPARα enhances antitumor activity via FoxO1 activation in follicular lymphoma"

Article Title: Dual targeting of PI3Kδ and PPARα enhances antitumor activity via FoxO1 activation in follicular lymphoma

Journal: Cell Death & Disease

doi: 10.1038/s41419-026-08593-5

Figure Legend Snippet: A - C EdU flow plots for Karpas-422, RL, and Sc-1 cells after 24-h treatment (Linperlisib 32 μM; Chiglitazar 16 μM). D – F Quantification of EdU-positive cells showing reduced DNA synthesis with the combination ( n = 3). G – L ( G , H ) for Karpas-422; ( I , J ) for RL; ( K , L ) for Sc-1. Cell-cycle distribution by PI staining, demonstrating G0/G1 accumulation with Linperlisib and further enhancement by the combination (Linperlisib 16 μM; Chiglitazar 8 μM; n = 3). M GSEA indicating negative enrichment of the G1/S transition pathway (NES = − 2.85865, p < 0.00001). N – P Western blots of G1/S checkpoint proteins (p27, Cyclin E1, CDK2, p-CDK2); combination treatment increased p27 and decreased Cyclin E1, CDK2, and p-CDK2 (representative of three independent experiments).

Techniques Used: DNA Synthesis, Staining, Western Blot

Western Blot:

Article Title: Discovery of a novel small molecule degrader of wild type and mutant estrogen receptors using DNA encoded libraries.
Article Snippet: The membrane was then washed with TBST (0.1% Tween 20 in TBS) and incubatedwith anHRP-linked secondary antibody.After the third wash, the target proteinswere visualized using the Super SignalWest Femto MaximumSensitivity substrate (ThermoFisher Scientific, Cat. 34096) using a ChemiDoc Imaging System (Bio-Rad). .. The antibodies used in the immunoblots were anti-ERα (Invitrogen, Cat. # MA1-27107), anti-cyclin D1 (Invitrogen, Cat. # MA5-42676), anti-survivin (Cell Signaling Technology (CST), Cat. # 2808S), anti-E2F1 (CST, Cat. # 3742), anti-TFF1 (CST, Cat. # 15571S), anti-cleaved PARP (CST, Cat. # 5625S), anti-PR A/B (CST, Cat. # 8757S), anti-c-MYC (CST, Cat. # 5605S), anti-GREB1 (Sigma, Cat. # MABS62), anti-CDK2 (CST, Cat. # 2546T) anti-β-actin (SCB; Cat. # SC4778) and anti-GAPDH (SCB; Cat. # SC-32233). ..

Article Title: Discovery of a novel small molecule degrader of wild type and mutant estrogen receptors using DNA encoded libraries
Article Snippet: After the third wash, the target proteins were visualized using the Super Signal West Femto Maximum Sensitivity substrate (ThermoFisher Scientific, Cat. 34096) using a ChemiDoc Imaging System (Bio-Rad). .. The antibodies used in the immunoblots were anti-ERα (Invitrogen, Cat. # MA1-27107), anti-cyclin D1 (Invitrogen, Cat. # MA5-42676), anti-survivin (Cell Signaling Technology (CST), Cat. # 2808S), anti-E2F1 (CST, Cat. # 3742), anti-TFF1 (CST, Cat. # 15571S), anti-cleaved PARP (CST, Cat. # 5625S), anti-PR A/B (CST, Cat. # 8757S), anti-c-MYC (CST, Cat. # 5605S), anti-GREB1 (Sigma, Cat. # MABS62), anti-CDK2 (CST, Cat. # 2546T) anti-β-actin (SCB; Cat. # SC-4778) and anti-GAPDH (SCB; Cat. # SC-32233). ..

Article Title: VIRMA-mediated SHQ1 m6A modification enhances liver regeneration through an HNRNPA2B1-dependent mechanism
Article Snippet: Samples of protein were resolved on sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto PVDF membranes (ISEQ00010, Millipore, Burlington, USA). .. The membranes were incubated with the following primary antibodies overnight at 4 °C: anti-VIRMA (68235-1-Ig, 1:1000, Proteintech, Wuhan, China), anti-CyclinD1 (#55506T, 1:1000, Cell Signaling Technology, Danvers, USA), anti-CyclinA2 (ab181591, 1:1000, Abcam, Cambridge, UK), anti-CDK2 (#2546, 1:1000, Cell Signaling Technology, Danvers, USA), anti-CyclinB1 (#4138, 1:1000,Cell Signaling Technology, Danvers, USA), anti-CDK1 (ab32094, 1:1000, Abcam, Cambridge, UK), anti-SHQ1 (bs-17473R-Bio, 1:500, bioss, Beijing, China), anti-p-AKT(Ser473) (#4060, 1:1000, Cell Signaling Technology, Danvers, USA), anti-t-AKT (#4691s, 1:1000, Cell Signaling Technology, Danvers, USA), anti-HNRNPA2B1 (14813-1-AP, 1:1000, Proteintech, Wuhan, China), anti- β -Tubulin (AF7011, 1:1000, Affinity, Jiangsu, China), anti-RICTOR (ab70374, 1:1000, abcam, Cambridge, UK), anti-GAPDH (200306, 1:5000, Zen BioScience, Chengdu, China), Secondary antibodies were pre-labelled at room temperature for 1 h. Western blots were quantified using ImageJ software (Version 1.53m). .. Total RNA was extracted by using Trizol reagent (Invitrogen, CA, USA).

Incubation:

Image Search Results

Journal: Cell Death & Disease

Article Title: Dual targeting of PI3Kδ and PPARα enhances antitumor activity via FoxO1 activation in follicular lymphoma

doi: 10.1038/s41419-026-08593-5

Figure Lengend Snippet: A - C EdU flow plots for Karpas-422, RL, and Sc-1 cells after 24-h treatment (Linperlisib 32 μM; Chiglitazar 16 μM). D – F Quantification of EdU-positive cells showing reduced DNA synthesis with the combination ( n = 3). G – L ( G , H ) for Karpas-422; ( I , J ) for RL; ( K , L ) for Sc-1. Cell-cycle distribution by PI staining, demonstrating G0/G1 accumulation with Linperlisib and further enhancement by the combination (Linperlisib 16 μM; Chiglitazar 8 μM; n = 3). M GSEA indicating negative enrichment of the G1/S transition pathway (NES = − 2.85865, p < 0.00001). N – P Western blots of G1/S checkpoint proteins (p27, Cyclin E1, CDK2, p-CDK2); combination treatment increased p27 and decreased Cyclin E1, CDK2, and p-CDK2 (representative of three independent experiments).

Article Snippet: The primary antibodies used were as follows: PI3K p110δ (A19742; ABclonal), pan-Akt (#4691; CST), phospho-Akt (Ser473, #4060; CST), PPARα (ab227074; Abcam), FoxO1 (#2880; CST), phospho-FoxO1 (Thr24, #9464; CST) and (Ser256, #9461; CST), FoxO3a (#12829; CST), FoxO4 (#9472; CST), Mcl-1 (#16225-1-AP; Proteintech), Bcl-2 (#12789-1-AP; Proteintech), Bim (A19702; ABclonal), Bax (#50599-2-Ig; Proteintech), Cleaved PARP(#5625; CST), P21(#2947; CST), p27 (#3686; CST), Cyclin E1 (#11935-1-AP; Proteintech), CDK2 (#10122-1-AP; Proteintech), phospho-CDK2 (#4539; CST), GLUT1(#73015; CST), PGK1(A12686; ABclonal), β-Tubulin (#10094-1-AP; Proteintech), Lamin B1 (#13435; CST), and β-Actin (#66009-1-Ig; Proteintech).

Techniques: DNA Synthesis, Staining, Western Blot

A) Schematic representation of RB1-E2F regulation during cell cycle. Phosphorylation of RB1 releases the E2F transcription factor, which activates the genes required for cell cycle progression. B) mRNA expression levels of E-type cyclins ( CCNE1 and CCNE2 ) and Dtype cyclins ( CCND1, CCND2 , and CCND3 ) were analyzed across normal prostate tissue, primary prostate cancer, metastatic prostate cancer, and castration-resistant prostate cancer using patient datasets obtained from accessed through betastasis.com. Error bars represent the standard error of the mean (SEM) and unpaired Mann-Whitney-Wilcoxon test was used to evaluate statistical significance. C and D) Gleason score distribution in prostate tumors over-expression CDK2 and / or CCNE1 and / or CCNE2 (exp > 2) accessed through the cBioPortal in the Prostate Adenocarcinoma (TCGA, Firehose Legacy) dataset and Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS 2019). Please, note that value of 11 is that recorded from cBioportal. D and E) Cell viability after 4 days of treatment with BLU-222 and Tagtociclib at the indicated concentrations (average of three biological replicates each with three technical replicates). Control samples were set to 100 and treatments were normalized to that. Error bars represent the SEM. F and G) Colony-formation assay after 7 days treatment with BLU-222 and Tagtociclib or CDK2 knockdown in C4-2 (3-4 biological replicates, paired two-tailed Student’s t -test (F) and one-sample t -test (G) were used to evaluate statistical significance and error bars represent the SEM. Western blot was used to confirm successful depletion of CDK2 after the knockdown (representative of three biological replicates).

Journal: bioRxiv

Article Title: Castration-resistant prostate cancer cells are addicted to the high activity of cyclin-dependent kinase 2

doi: 10.64898/2026.03.17.712428

Figure Lengend Snippet: A) Schematic representation of RB1-E2F regulation during cell cycle. Phosphorylation of RB1 releases the E2F transcription factor, which activates the genes required for cell cycle progression. B) mRNA expression levels of E-type cyclins ( CCNE1 and CCNE2 ) and Dtype cyclins ( CCND1, CCND2 , and CCND3 ) were analyzed across normal prostate tissue, primary prostate cancer, metastatic prostate cancer, and castration-resistant prostate cancer using patient datasets obtained from accessed through betastasis.com. Error bars represent the standard error of the mean (SEM) and unpaired Mann-Whitney-Wilcoxon test was used to evaluate statistical significance. C and D) Gleason score distribution in prostate tumors over-expression CDK2 and / or CCNE1 and / or CCNE2 (exp > 2) accessed through the cBioPortal in the Prostate Adenocarcinoma (TCGA, Firehose Legacy) dataset and Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS 2019). Please, note that value of 11 is that recorded from cBioportal. D and E) Cell viability after 4 days of treatment with BLU-222 and Tagtociclib at the indicated concentrations (average of three biological replicates each with three technical replicates). Control samples were set to 100 and treatments were normalized to that. Error bars represent the SEM. F and G) Colony-formation assay after 7 days treatment with BLU-222 and Tagtociclib or CDK2 knockdown in C4-2 (3-4 biological replicates, paired two-tailed Student’s t -test (F) and one-sample t -test (G) were used to evaluate statistical significance and error bars represent the SEM. Western blot was used to confirm successful depletion of CDK2 after the knockdown (representative of three biological replicates).

Article Snippet: Antibodies were obtained from: Cell Signaling Technologies: CDK2 (2546), Proteintech: p53 (60283-2-Ig), and Abcam: Actin (ab49900).

Techniques: Phospho-proteomics, Expressing, MANN-WHITNEY, Over Expression, Control, Colony Assay, Knockdown, Two Tailed Test, Western Blot

A) Parental and BLU-222-resistant C4-2 cells were treated with BLU-222 as indicated and cell viability was assessed after 4 days of treatment (four biological replicates, each 6 technical replicates and paired two-tailed Student’s t -test was used to assess significance. GraphPad Prism was used to calculate IC 50 -values. Error bars represent the SEM. B and C) Parental and BLU-222-resistant C4-2 cells were treated with the selective CDK2 inhibitor Tagtociclib or the pan-CDK inhibitor AT7519 and viability assessed (the rest is the same as in 2A). D) RT-qPCR analysis of parental and BLU-222 resistant C4-2 cells after the indicated treatments. Data is from 3-4 biological replicates, error bars represent the SEM and statistical significance is evaluated by one sample t -test. E) Parental and BLU-222-resistant C4-2 cells were treated with the CDK4/6 inhibitor Abemaciclib and Palbociclib for 4 days and the rest is the same as in 2A.

Journal: bioRxiv

Article Title: Castration-resistant prostate cancer cells are addicted to the high activity of cyclin-dependent kinase 2

doi: 10.64898/2026.03.17.712428

Figure Lengend Snippet: A) Parental and BLU-222-resistant C4-2 cells were treated with BLU-222 as indicated and cell viability was assessed after 4 days of treatment (four biological replicates, each 6 technical replicates and paired two-tailed Student’s t -test was used to assess significance. GraphPad Prism was used to calculate IC 50 -values. Error bars represent the SEM. B and C) Parental and BLU-222-resistant C4-2 cells were treated with the selective CDK2 inhibitor Tagtociclib or the pan-CDK inhibitor AT7519 and viability assessed (the rest is the same as in 2A). D) RT-qPCR analysis of parental and BLU-222 resistant C4-2 cells after the indicated treatments. Data is from 3-4 biological replicates, error bars represent the SEM and statistical significance is evaluated by one sample t -test. E) Parental and BLU-222-resistant C4-2 cells were treated with the CDK4/6 inhibitor Abemaciclib and Palbociclib for 4 days and the rest is the same as in 2A.

Article Snippet: Antibodies were obtained from: Cell Signaling Technologies: CDK2 (2546), Proteintech: p53 (60283-2-Ig), and Abcam: Actin (ab49900).

Techniques: Two Tailed Test, Quantitative RT-PCR

A) C4-2 cells were treated with BLU-222 (500 nM) and Tagtociclib (500 nM) for 3 days, R-loop accumulation was detected using immunofluorescence (the S9.6 antibody), and TP53BP1 was also detected. Quantification of signal intensity with SEM and significance was assessed by paired two-tailed Student’s t -test. B) CRPC cell lines (C4-2 and 22RV1) and normal prostate epithelial cells (PNT1) were treated for 4 days with CX-5461 or Everolimus alone, or in combination with BLU-222 (500 nM) or Tagtociclib (500 nM), cell viability assessed and data is the mean of four biological replicates (2-3 technical replicates each) with SEM. Paired two-tailed Student’s t -test was used to evaluate statistical significance, which is indicated in comparison between CDK2 inhibitor-alone and compound of interest-alone to combination and is color-coded according to CDK2 inhibitor used. C) Colony-formation assay. Cells were either not radiated (0), first radiated and then treated after 1 day (R>C), first treated and then radiated after 1 day (C>R) or treated and radiated at the same time (CR). After 7 days, the colonies were detected (4 biological replicates with SEM). Paired two-tailed Student’s t -test was used to evaluate statistical significance and the value reported is in comparison to both radiation-alone and CDK2 inhibitor-alone (whichever is higher, is reported).

Journal: bioRxiv

Article Title: Castration-resistant prostate cancer cells are addicted to the high activity of cyclin-dependent kinase 2

doi: 10.64898/2026.03.17.712428

Figure Lengend Snippet: A) C4-2 cells were treated with BLU-222 (500 nM) and Tagtociclib (500 nM) for 3 days, R-loop accumulation was detected using immunofluorescence (the S9.6 antibody), and TP53BP1 was also detected. Quantification of signal intensity with SEM and significance was assessed by paired two-tailed Student’s t -test. B) CRPC cell lines (C4-2 and 22RV1) and normal prostate epithelial cells (PNT1) were treated for 4 days with CX-5461 or Everolimus alone, or in combination with BLU-222 (500 nM) or Tagtociclib (500 nM), cell viability assessed and data is the mean of four biological replicates (2-3 technical replicates each) with SEM. Paired two-tailed Student’s t -test was used to evaluate statistical significance, which is indicated in comparison between CDK2 inhibitor-alone and compound of interest-alone to combination and is color-coded according to CDK2 inhibitor used. C) Colony-formation assay. Cells were either not radiated (0), first radiated and then treated after 1 day (R>C), first treated and then radiated after 1 day (C>R) or treated and radiated at the same time (CR). After 7 days, the colonies were detected (4 biological replicates with SEM). Paired two-tailed Student’s t -test was used to evaluate statistical significance and the value reported is in comparison to both radiation-alone and CDK2 inhibitor-alone (whichever is higher, is reported).

Article Snippet: Antibodies were obtained from: Cell Signaling Technologies: CDK2 (2546), Proteintech: p53 (60283-2-Ig), and Abcam: Actin (ab49900).

Techniques: Immunofluorescence, Two Tailed Test, Comparison, Colony Assay

A-D) CRPC cell lines (C4-2 and 22Rv1), cell lines derived from normal prostate epithelia (PNT1 and RWPE-1), and prostate cancer cells (LNCaP) were treated for 4 days as indicated (BLU-222: 500 nM and Tagtociclib: 500 nM), viability assay performed and data is the mean of four biological replicates (2-3 technical replicates each) with SEM. Paired two-tailed Student’s t -test was used to evaluate statistical significance, which is indicated in comparison between CDK2 inhibitor-alone and compound of interest-alone to combination and is color-coded according to CDK2 inhibitor used. E) Colony-formation assay. Cells were treated as indicated and colony-formation assay performed after 7 days (3 biological replicates with SEM and paired two-tailed Student’s t -test was used to assess the significance).

Journal: bioRxiv

Article Title: Castration-resistant prostate cancer cells are addicted to the high activity of cyclin-dependent kinase 2

doi: 10.64898/2026.03.17.712428

Figure Lengend Snippet: A-D) CRPC cell lines (C4-2 and 22Rv1), cell lines derived from normal prostate epithelia (PNT1 and RWPE-1), and prostate cancer cells (LNCaP) were treated for 4 days as indicated (BLU-222: 500 nM and Tagtociclib: 500 nM), viability assay performed and data is the mean of four biological replicates (2-3 technical replicates each) with SEM. Paired two-tailed Student’s t -test was used to evaluate statistical significance, which is indicated in comparison between CDK2 inhibitor-alone and compound of interest-alone to combination and is color-coded according to CDK2 inhibitor used. E) Colony-formation assay. Cells were treated as indicated and colony-formation assay performed after 7 days (3 biological replicates with SEM and paired two-tailed Student’s t -test was used to assess the significance).

Article Snippet: Antibodies were obtained from: Cell Signaling Technologies: CDK2 (2546), Proteintech: p53 (60283-2-Ig), and Abcam: Actin (ab49900).

Techniques: Derivative Assay, Viability Assay, Two Tailed Test, Comparison, Colony Assay

A) CRPC cell lines C4-2 and 22Rv1 were treated with BLU-222 or Tagtociclib for 48 hours. mRNA levels of AR and AR target genes were measured by qPCR. For C4-2 cells, AR, KLK3, and TMPRSS2 expression were analyzed, whereas for 22RV1 cells, AR, KLK3, and GAPDH expression were analyzed. Boxplots represent data from 2-3 biological replicates. Error bars represent the SEM. B) mRNA levels of AR and AR target genes, KLK3, and GAPDH were quantified by qPCR in parental and BLU-222-resistant C4-2 cells. Data is from four biological replicates with SEM. C) Pathology classification of prostate tumors over-expressing CDK2 and / or CCNE1 and / or CCNE2 (exp > 2) accessed through the cBioPortal in the Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS 2019).

Journal: bioRxiv

Article Title: Castration-resistant prostate cancer cells are addicted to the high activity of cyclin-dependent kinase 2

doi: 10.64898/2026.03.17.712428

Figure Lengend Snippet: A) CRPC cell lines C4-2 and 22Rv1 were treated with BLU-222 or Tagtociclib for 48 hours. mRNA levels of AR and AR target genes were measured by qPCR. For C4-2 cells, AR, KLK3, and TMPRSS2 expression were analyzed, whereas for 22RV1 cells, AR, KLK3, and GAPDH expression were analyzed. Boxplots represent data from 2-3 biological replicates. Error bars represent the SEM. B) mRNA levels of AR and AR target genes, KLK3, and GAPDH were quantified by qPCR in parental and BLU-222-resistant C4-2 cells. Data is from four biological replicates with SEM. C) Pathology classification of prostate tumors over-expressing CDK2 and / or CCNE1 and / or CCNE2 (exp > 2) accessed through the cBioPortal in the Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS 2019).

Article Snippet: Antibodies were obtained from: Cell Signaling Technologies: CDK2 (2546), Proteintech: p53 (60283-2-Ig), and Abcam: Actin (ab49900).

Techniques: Expressing

Review

phospho cdk2 (Cell Signaling Technology Inc)

Structured Review

Images

1) Product Images from "Dual targeting of PI3Kδ and PPARα enhances antitumor activity via FoxO1 activation in follicular lymphoma"

Related Articles

Western Blot:

Incubation:

Similar Products

Image Search Results